# Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet.

> PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42076092-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42076092-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42076092-semaglutide-v1.json
- Content SHA-256: `5a6ada18e17bdd04329ed93ccb62df001feb34fe32e373b2d38c6503675661cf`

## Claims and source pins

### Headline

Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

### Summary

PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

### Paragraph 1

PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

## Sources

<a id="source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672"></a>
- **Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. · retained source version 1:2026-08-13:current:2e51dea7a67206253f86e951e4444f4bbb8d67075ec302936bcf4500ae72849d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42076092/) (`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-42076092-semaglutide-v1.json SHA-256: 5a6ada18e17bdd04329ed93ccb62df001feb34fe32e373b2d38c6503675661cf.